Beta-blockers Cut Mortality Risk in Dialysis Patients with Heart Failure, Study Shows

According to a study that the use of beta-blockers seems to cut the risk of mortality in patients with heart failure (HF) who are starting either hemodialysis or peritoneal dialysis.

Photo: Patient Undergoing Dialysis | InStyleHealth


Research covered 3,503 adult patients with chronic kidney disease and HF. A total of 2,115 (60.4%) were using beta-blockers when they transitioned to maintenance dialysis.

Results evaluated were all-cause mortality within 6 months and hospitalization within 6 months after the transition to dialysis. Using the cox proportional hazard analysis and logistic regression to estimate the effect of beta-blocker treatment on the said outcomes. Furthermore, inverse probability of treatment weighs using propensity scores was applied in order to balance covariates between users and non-users of beta-blockers.

Comparing with non-users, users were less likely to die of any cause within 6 months. Generally, any beta-blocker conferred a 21% risk reduction, whereas metoprolol lowered the risk by 32%.

Protective benefit of beta-blockers was not observed for all-cause or cardiovascular-related hospitalization within 6 months.

According to researchers that the study was limited by its observational nature as well as the failure to fully account for residual confounding.

 

Source: Am J Kidney Dis 2021;77:704-712

If you have any suggestions, please let us know.

Post a Comment (0)
Previous Post Next Post